(1997). A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium Limbach et al.
(2009). A: A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine
(2010). A: Protection from malaria sporozoite challenge correlates with frequency of TRAP-specific CD8+ T cells secreting IFNγ [abstract]. Malaria: New Approaches to Understanding Host-Parasite Interactions
(2002). Alpers M: A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis
(1997). Compact, synthetic, vaccinia virus early/ late promoter for protein expression. Biotechniques
(2002). D: A proteomic view of the Plasmodium falciparum life cycle. Nature
(2004). D: High-throughput generation of P. falciparum functional molecules by recombinational cloning. Genome Res
(2009). Discovering novel pre-erythrocytic antigens for malaria [abstract]. Am J Trop Med Hyg
(2009). Doumbo O: Allele-specific efficacy of an AMA-1-based malaria subunit vaccine [abstract]. Am J Trop Med Hyg
(1989). E: Cloning and expression of foreign genes in vaccinia virus, using a host range selection system.
(1987). E: Vaccinia virus as an expression vector. Methods Enzymol
(1990). Felgner P: Direct gene transfer into mouse muscle in vivo. Science
(2009). for the MSP-1 Malaria Vaccine Working Group: Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One
(2010). Heussler V: Exoerythrocytic Plasmodium parasites secrete a cysteine protease inhibitor involved in sporozoite invasion and capable of blocking cell death of host hepatocytes. PLoS Pathog
(2000). Hoffman S: Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigenexpressing recombinant poxvirus.
(1996). Hoffman SL: Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity.
(2003). HP: etramps, a new Plasmodium falciparum gene family coding for developmentally regulated and highly charged membrane proteins located at the parasite-host cell interface. Mol Biol Cell
(2006). Kneteman N: Plasmodium falciparum infection and exoerythrocytic development in mice with chimeric human livers.
(2009). Malaria Report
(2008). Peng X: Assessment and improvement of the Plasmodium yoelii yoelii genome annotation through comparative analysis. Bioinformatics
(2007). Protracted sterile protection with Plasmodium yoelii preerythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J Infect Dis
(1987). RL: Characterization of Plasmodium yoelii monoclonal antibodies directed against stagespecific sporozoite antigens. Infect Immun
(2006). Rosenthal PJ: Falstatin, a cysteine protease inhibitor of Plasmodium falciparum, facilitates erythrocyte invasion. PLoS Pathog
(2004). S: Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun
(2002). S: Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage.
(2008). S: Interaction of an atypical Plasmodium falciparum ETRAMP with human apolipoproteins.
(2007). S: L-FABP is a critical host factor for successful malaria liver stage development.